Course and management of allogeneic stem cell transplantation in patients with mitochondrial neurogastrointestinal encephalomyopathy

Journal of Neurology

Volumn 259, Issue 12, 2012, Pages 2699-2706

  Filosto, Massimiliano ^a   Scarpelli, Mauro ^a   Tonin, Paola ^a   Lucchini, Giovanna ^a   Pavan, Fabio ^a   Santus, Francesca ^b   Parini, Rossella ^b   Donati, Maria Alice ^b   Cotelli, Maria Sofia ^b   Vielmi, Valentina ^c   Todeschini, Alice ^c   Canonico, Francesco ^c   Tomelleri, Giuliano ^d   Padovani, Alessandro ^d   Rovelli, Attilio ^c  

^a SPEDALI CIVILI   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Allogeneic hematopoietic stem cell transplantation; HSCT; Mitochondrial neurogastrointestinal encephalomyopathy; MNGIE; Posterior reversible encephalopathy syndrome; PRES

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; ANTIBIOTIC AGENT; BUDESONIDE; BUSULFAN; COTRIMOXAZOLE; CYCLOSPORIN A; DEXAMETHASONE; ETANERCEPT; ETIRACETAM; FLUDARABINE; FOLINIC ACID; GANCICLOVIR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; THIAMINE; THYMOCYTE ANTIBODY;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC THERAPY; ARTICLE; BONE MARROW CELL; CACHEXIA; CASE REPORT; CHIMERA; CLOSTRIDIUM DIFFICILE; CONSTIPATION; CYTOMEGALOVIRUS INFECTION; DEATH; DIARRHEA; DISEASE COURSE; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; FOLLOW UP; FUNCTIONAL NEUROIMAGING; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL OBSTRUCTION; GENE DELETION; GLASGOW COMA SCALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMORRHAGIC CYSTITIS; HLA SYSTEM; HUMAN; HYPERGLYCEMIA; INFECTIOUS DIARRHEA; INTESTINE PSEUDOOBSTRUCTION; KARNOFSKY PERFORMANCE STATUS; LIMB PAIN; LYMPHOCYTE COUNT; MEDICAL HISTORY; MNGIE SYNDROME; MORBIDITY; MORTALITY; MUSCLE ATROPHY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCOLITIS; PANCREATITIS; PARESTHESIA; PNEUMONIA; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; PTOSIS; PUVA; PYREXIA IDIOPATHICA; REDUCED INTENSITY CONDITIONING; RESPIRATORY DISTRESS; SEPTIC SHOCK; SEPTICEMIA; SHOCK; STOMATITIS; TOTAL PARENTERAL NUTRITION; UNRELATED DONORS; VIRUS REACTIVATION; VOMITING;

ADULT; DISEASE MANAGEMENT; FATAL OUTCOME; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INTESTINAL PSEUDO-OBSTRUCTION; MITOCHONDRIAL ENCEPHALOMYOPATHIES; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84872102223     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6572-9     Document Type: Article

References (35)

1. Nishino I, Spinazzola A, Hirano M (1999) Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 283:689-692
2. Nishino I, Spinazzola A, Papadimitriou A et al (2000) Mitochondrial neurogastrointestinal encephalomyopathy: an autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 47:792-800
3. Nishigaki Y, Martí R, Copeland WC, Hirano M (2003) Sitespecific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest 111: 1913-1921
4. Garone C, Tadesse S, Hirano M (2011) Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain 134:3326-3332
5. Lara MC, Weiss B, Illa I et al (2006) Infusion of platelets transiently reduces nucleoside overload in MNGIE. Neurology 67:1461-1463
6. Moran NF, Bain MD, Muquit MM, Bax BE (2008) Carrier erythrocyte entrapped thymidine phosphorylase therapy for MNGIE. Neurology 71:686-688
7. Yavuz H, Ozel A, Christensen M et al (2007) Treatment of mitochondrial neurogastrointestinal encephalomyopathy with dialysis. Arch Neurol 64:435-438
8. Torres-Torronteras J, Gómez A, Eixarch H et al (2011) Hematopoietic gene therapy restores thymidine phosphorylase activity in a cell culture and a murine model of MNGIE. Gene Ther 18:795-806
9. Hirano M, Marti R, Casali C et al (2006) Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 67:1458-1460
10. Halter J, Schǔpbach WM, Casali C et al (2011) Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant 46:330-337
11. Filosto M, Scarpelli M, Tonin P et al (2011) Pitfalls in diagnosing mitochondrial neurogastrointestinal encephalomyopathy. J Inherit Metab Dis 34:1199-1203
12. Filipovich AH, Weisdorf D, Pavletic S et al (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11:945-956
13. Soni S, Skeens M, Gross TE et al (2009) Outcome after addition of rabbit-ATG to the standard Bu ? Cy regimen for allogeneic matched sibling donor hematopoietic stem cell transplantation for hemoglobinopathies in children. Cell Ther Transplant 2:113-114
14. Bonifazi F, Bandini G, Colaci E et al (2009) Less extensive chronic GvHD with PBSC and ATG for sibling transplant without increase in TRM or relapse. Bone Marrow Transplant 43(Suppl 1):S10
15. Crocchiolo R, Castagna L, El-Cheikh J et al (2011) Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Exp Hematol 39:892-896
16. Dominietto A, Tedone E, Soracco M et al (2012) In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. Bone Marrow Transplant 47:101-106
17. Martí R, Spinazzola A, Tadesse S, Nishino I, Nishigaki Y, Hirano M (2004) Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays. Clin Chem 50:120-124
18. Shoffner JM. Mitochondrial Neurogastrointestinal Encephalopathy Disease. In: Pagon RA, Bird TC, Dolan CR, Stephens K, editors. GeneReviews (internet). University of Washington, Seattle; 1993-2005. (updated 11 May 2010)
19. Appelbaum FR (2007) Hematopoietic-cell transplantation at 50. N Engl J Med 357:1472-1475
20. Boelens JJ, Prasad VK, Tolar J, Wynn RF, Peters C (2010) Current international perspectives on hematopoietic stem cell transplantation for inherited metabolic disorders. Pediatr Clin North Am 57:123-145
21. Rovelli AM (2008) The controversial and changing role of hematopoietic cell transplantation for lysosomal storage disorders: an update. Bone Marrow Transplant 41:S87-S89
22. Scarpelli M, Cotelli MS, Mancuso M et al (2010) Current options in the treatment of mitochondrial diseases. Recent Pat CNS Drug Discov 5:203-209
23. Lee SJ, Klein J, Haagenson M et al (2007) High-resolution donorrecipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 110:4576-4583
24. Mead AJ, Thomson KJ, Morris EC et al (2010) HLA-mismatched unrelated donors are a viable alternate graft source for allogeneic transplantation following alemtuzumab-based reduced-intensity conditioning. Blood 115:5147-5153
25. Krǒger N, Zabelina T, Binder T et al (2009) HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen. Biol Blood Marrow Transplant 15:454-462
26. Crocchiolo R, Ciceri F, Fleischhauer K et al (2009) HLA matching affects clinical outcome of adult patients undergoing haematopoietic SCT from unrelated donors: a study from the Gruppo Italiano Trapianto di Midollo Osseo and Italian Bone Marrow Donor Registry. Bone Marrow Transplant 44:571-577
27. Ferrara JL, Levine JE, Reddy P, Holler E (2009) Graft-versushost disease. Lancet 373:1550-1561
28. Finke J, Schmoor C, Lang H et al (2003) Matched and mismatched allogeneic stem-cell transplantation from unrelated donors using combined graft-versus-host disease prophylaxis including rabbit anti-T lymphocyte globulin. J Clin Oncol 21:506-513
29. Finke J, Bethge WA, Schmoor C et al (2009) Standard graftversus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. Lancet Oncol 10:855-864
30. Giralt S (2011) ATG and RIC: not a good match? Blood 117:6744-6745
31. Bartynski WS (2008) Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features. Am J Neuroradiol 29:1036-1042
32. Walter SH, Bertz H, Gerling J (2000) Bilateral optic neuropathy after bone marrow transplantation and cyclosporin A therapy. Graefes Arch Clin Exp Ophthalmol 238:472-476
33. Halter J, Schǔpbach WMM, Casali C et al (2011) Allogeneic HSCT for mitochondrial neurogastrointestinal encephalomyopathy: the first promising effective treatment option in an otherwise unrelenting progressive disease? Bone Marrow Transplant 46(S1):O398 (abstract)
34. Sicurelli F, Carluccio MA, Toraldo F et al (2012) Clinical and biochemical improvement following HSCT in a patient with MNGIE: 1-year follow-up. J Neurol. doi:10.1007/s00415-012-6500-z
35. Peters C, Cornish JM, Parikh SH, Kurtzberg J (2010) Stem cell source and outcome after hematopoietic stem cell transplantation (HSCT) in children and adolescents with acute leukemia. Pediatr Clin N Am 57:27-46